World Intellectual Property Organization

Mitsubishi Electric Ranked 4th Globally and 1st Among Japanese Companies in International Patent Applications Filed in 2023

Retrieved on: 
Friday, March 8, 2024
Consumer Electronics, Technology, Manufacturing, Other Technology, Software, Other Manufacturing, Hardware, World Intellectual Property Organization, IP, Patent, Growth, WIPO, Mitsubishi Electric

Mitsubishi Electric Corporation (TOKYO:6503) announced today that it ranked fourth globally and first among Japanese companies in terms of international patent applications filed in 2023 according to the Switzerland-based World Intellectual Property Organization (WIPO).

Key Points: 
  • Mitsubishi Electric Corporation (TOKYO:6503) announced today that it ranked fourth globally and first among Japanese companies in terms of international patent applications filed in 2023 according to the Switzerland-based World Intellectual Property Organization (WIPO).
  • A high level of both ranking and the number of patent applications reflect Mitsubishi Electric’s strategy to actively promote international patent applicants along with the globalization of its business.
  • In 2023, the company has ranked within the top five global companies in international patent applications by company for ten consecutive years since 2014, and first among all Japanese companies for nine consecutive years.
  • Going forward, Mitsubishi Electric will continue strengthening its IP activities to address social challenges and deliver new value towards sustainability through our business.

Innovation at the forefront at Business of IP Asia Forum and Entrepreneur Day

Retrieved on: 
Sunday, November 26, 2023
SME, Marketing, Associate, Invention, Convention center, Recycling, Government, Commerce, Waste management, Workplace, World Intellectual Property Organization, Hang Seng Bank, Ideation, Amazon Web Services, Microsoft, Interview, I&T, Forum, Senior counsel, HKTDC, Vitality, Entrepreneurship, HKSAR, Exhibition, IP, Clean technology, Black Book, Groupe MCM, Start, Policy, GBA, Ecosystem, Intellectual property, Incubator, HRMS, International, Patent, WIPO, AI, Economic development, Investment, NVIDIA, APEC, ITU, Acquisition, Express

The Hong Kong Special Administrative Region Government (HKSAR Government) and Hong Kong Trade Development Council (HKTDC), will hold the 13th Business of IP Asia Forum (BIP Asia Forum) from 7 December to 8 December.

Key Points: 
  • The Hong Kong Special Administrative Region Government (HKSAR Government) and Hong Kong Trade Development Council (HKTDC), will hold the 13th Business of IP Asia Forum (BIP Asia Forum) from 7 December to 8 December.
  • HKTDC Deputy Executive Director Patrick Lau said, "The BIP Asia Forum and Entrepreneur Day are held concurrently to provide a holistic presentation of the journey from ideation and IP commercialisation to starting your business and scaling up.
  • Business of IP Asia Forum: Steering New Economic Growth
    Themed "IP & Innovation: Steering New Economic Growth", the Forum brings together IP industry players and business leaders from around the world to discuss the latest IP developments and explore collaboration opportunities.
  • Business of IP Asia Forum website: https://bipasia.hktdc.com/en/
    Media representatives can complete the following form by December 7(Thursday) and email to [email protected] for pre-registration to receive a confirmation email for browsing Exhibition and Forum Website.

Council for Innovation Promotion Urges Biden Admin to Oppose IP Waiver

Retrieved on: 
Tuesday, December 5, 2023
World Trade Organization, Creativity, IP, UN, Commerce, Patient, Council, Defense, Therapy, Conference, World Intellectual Property Organization, Patent, COVID-19 vaccine, Innovation, COVID-19, Letter, Government, Pharmaceutical industry

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Yesterday, the Council for Innovation Promotion (C4IP) and nearly 50 former government officials and intellectual property experts sent a letter to President Biden urging his administration to oppose the World Trade Organization's proposed IP waiver for Covid-19 therapeutics and diagnostics.

Key Points: 
  • WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Yesterday, the Council for Innovation Promotion (C4IP) and nearly 50 former government officials and intellectual property experts sent a letter to President Biden urging his administration to oppose the World Trade Organization's proposed IP waiver for Covid-19 therapeutics and diagnostics.
  • "The Council for Innovation Promotion is honored to lead this distinguished group in advocating for the preservation of global IP rights," said Frank Cullen, C4IP executive director.
  • "IP drives creativity and innovation worldwide, and the bipartisan solidarity of this group sends a clear message about the importance of maintaining these safeguards.
  • We hope the Biden administration strongly considers these experts' voices when evaluating the WTO's proposed IP waiver."

Global Times: Xi's inspection tour elevates Shanghai's leading role in high-quality development

Retrieved on: 
Tuesday, December 5, 2023
World Intellectual Property Organization, Belt, Yangtze Delta, Shanghai Futures Exchange, Sci-Tech Daresbury, Central Economic Work Conference, CPC, GDP, Hoxhaism, Science, Government, NEVS, Belt and Road Initiative, Communist party, Conference, Semiconductor, Central committee, Exhibition, Speech, Real-time, Global Innovation Index, Pudong, Global Times, Central Military Commission (China), Economic development, Tunnel, Information technology, Management, Manufacturing, Film industry, Tourism, Renewable energy, NEV, Xinhua News Agency, Xi

Such a focus from the top leader paints a clear picture of China's long-term development priorities and the path to Chinese modernization, they noted.

Key Points: 
  • Such a focus from the top leader paints a clear picture of China's long-term development priorities and the path to Chinese modernization, they noted.
  • He also urged Shanghai to accelerate building itself into a modern, socialist and international metropolis with global influence, and play a leading and exemplary role in advancing Chinese modernization, according to Xinhua.
  • The top leader's trip and important remarks have boosted confidence of local officials and businesses in pursuing high-quality development in various areas.
  • What the top leader focused on during the inspection tour also carries national significance, given Shanghai's leading and exemplary role in China's overall economic development, experts noted.

1st China Int'l Supply Chain Expo held in Beijing

Retrieved on: 
Friday, December 1, 2023
Research, Australia-China Council, International, International Chamber of Commerce, Commerce, Multimedia, UNCTAD, BDA China Limited, Alabama International Trade Center, World Intellectual Property Organization, The Business Council, Conference, Digital technology, Development, Speech, CISCE, United Nations, Video game

BEIJING, Dec. 1, 2023 /PRNewswire/ -- The first China International Supply Chain Expo (CISCE), themed "Connecting the World for a Shared Future," kicked off in Beijing on Nov. 28.

Key Points: 
  • BEIJING, Dec. 1, 2023 /PRNewswire/ -- The first China International Supply Chain Expo (CISCE), themed "Connecting the World for a Shared Future," kicked off in Beijing on Nov. 28.
  • It is also an international public product China offers to the world.
  • With a total exhibition area of 100,000 square meters, the expo includes five areas dedicated to supply chains for smart vehicle, green agriculture, clean energy, digital technology, and healthy living, as well as a supply chain service exhibition area.
  • Exhibitors from abroad account for 26% of the total participants at the expo.

CMS and IPDefine Announce Global Patent Monetisation Initiative

Retrieved on: 
Tuesday, November 21, 2023
Safety, International law, IP, Reputational damage, WIPO, World Intellectual Property Organization, CMS, Internet, Intellectual property, Patent, Book

TOKYO, Nov. 20, 2023 /PRNewswire/ -- International law firm CMS, in collaboration with patent AI specialist IPDefine Ltd., have developed a cutting-edge turnkey solution which is poised to make intellectual property monetisation more accessible than ever before.

Key Points: 
  • TOKYO, Nov. 20, 2023 /PRNewswire/ -- International law firm CMS, in collaboration with patent AI specialist IPDefine Ltd., have developed a cutting-edge turnkey solution which is poised to make intellectual property monetisation more accessible than ever before.
  • By switching the focus from maintenance to monetisation, businesses can transform their patent portfolio from a cost centre to a profit leader.
  • IPDefine CEO Aaron Mollin comments: "CMS Umbra is a powerful tool, which can give businesses access to accurate valuation and crucial strategic insight on their patent portfolios.
  • To find out more about CMS Umbra, please visit: Patent commercialisation | CMS Umbra | Data Driven Disputes

First BRST Draws Attendees from Over 80 Countries to Boost Science and Tech Collaboration

Retrieved on: 
Tuesday, November 7, 2023
Massachusetts Innovation & Technology Exchange, NUS, Belt, Innovation, National University of Singapore, Multilateralism, Science, technology, engineering, and mathematics, World Intellectual Property Organization, Global Innovation through Science and Technology initiative, Conference, Acquisition, Committee on Data of the International Science Council, Belt and Road Forum for International Cooperation, Development, National Medal of Technology and Innovation, BRST, Machine learning, National university, BRI, Nobel Prize, Belt and Road Initiative, Letter, Cryptocurrency, Management, Science, Physics, Xinhua News Agency

Chinese President Xi Jinping sent a congratulatory letter to the first BRST.

Key Points: 
  • Chinese President Xi Jinping sent a congratulatory letter to the first BRST.
  • Over 300 international guests from over 80 countries participated in the conference, including Nobel Prize winners, foreign academicians, experts, scholars, and presidents of well-known foreign universities.
  • The conference released the International Science and Technology Cooperation Initiative, advocating and practicing the concept of international science and technology cooperation that is open, fair, just and non-discriminatory, and working together to build a global science and technology community.
  • He foresees a future where robots specialized in data acquisition will create vast datasets for machine learning, significantly advancing material science.

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Wednesday, November 1, 2023
Research, AD, Food, Health care, Biomarker, ATCC, Macrophage, World Intellectual Property Organization, Data, White matter, Phase, MHRA, MRI, MDS, CELL, Hereditary leiomyomatosis and renal cell cancer syndrome, Prostate cancer, Dementia, China International Search and Rescue Team, ATCC (company), Phagocytosis, EEG, Cancer, Patient, MS, BOCA, Human, Neurodegenerative disease, Conference, CTA, Patent Cooperation Treaty, AAIC, PCT, NK, Brain, Remyelination, Grey, AML, Carcinoma, FDA, IND, Medication, CNS, Treatment-resistant depression, Drug development, Pharmacotherapy, Neuroinflammation, WIPO, Cross, Cognition, Vaccine, Pharmaceutical industry, Medical imaging, Cryptocurrency, Health, Immunotherapy, Disease

BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.
  • Recruitment of the trial is increasing and the company anticipates results of the Phase II program towards the end of 2024.
  • Other expense was approximately $0.0 million for the quarter ended September 30, 2023, compared to approximately $0.3 million during the quarter ended September 30, 2022.
  • Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.

WISeKey’s Subsidiary, SEALSQ Corp Announces New Board Member

Retrieved on: 
Wednesday, November 1, 2023
Internet of things, WIHN, Diplomacy, Paul H. Nitze School of Advanced International Studies, Council, LAES, WKEY, Shandong University, Berkman Klein Center for Internet & Society, Great Lakes region, World Intellectual Property Organization, Advisory board, Samuel Russell (Yale co-founder), Szeged Faculty of Law and Public Administration, Fourth Industrial Revolution, Wharton School of the University of Pennsylvania, WIPO, Independent, Columbia University, Massachusetts Institute of Technology, WEF, Harvard University, Semiconductor, Management

Mr. Kerimi brings to the Board extensive experience in technology, public relations, corporate strategy, and diplomacy across diverse global markets.

Key Points: 
  • Mr. Kerimi brings to the Board extensive experience in technology, public relations, corporate strategy, and diplomacy across diverse global markets.
  • Currently, Mr. Kerimi works with several multinational organizations including: the Independent Oversight Advisory Committee of the World Intellectual Property Organization (WIPO), the Advisory Board of World Smart Sustainable Cities Organization, and the Board of the Council of the Great Lakes Region.
  • Carlos Moreira, CEO of SEALSQ noted, “We are pleased to welcome Danil as a member of our Board.
  • His unique insights and the vast wealth of expertise in technology and corporate strategy will greatly benefit SEALSQ and will be invaluable to our board.

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

Retrieved on: 
Tuesday, October 31, 2023
Patient, IND, PSA, Patent, Leukemia, Progression-free survival, Biomarker, Art, Ligand, World Intellectual Property Organization, CD15, Invention, CELL, Hematological Cancer Research Investment and Education Act, Patent Cooperation Treaty, Cell, EPO, Administration, China International Search and Rescue Team, Disease, ATCC (company), NK, Cancer, WIPO, CT, Blood, TME, General counsel, CD2, Immunosuppression, Hypoxia, Insurance, Vaccine, Pharmaceutical industry

Boca Raton, Florida, Oct. 31, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced an update regarding the company’s patent covering its proprietary cell line, “INB16”, as well as the therapeutic composition comprising replication-incompetent INB16 cells known as “INKmune™” and methods of treating cancer by administering INKmune™, with a goal of achieving in vivo priming of natural killer (NK) cells to enhance the ability of a patient’s own NK-cells to effect cancer surveillance, recognition, and killing.

Key Points: 
  • INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition.
  • The application discloses and claims the novel INB16 cell line on deposit with the American Type Culture Collection, as well as compositions comprising replication incompetent INB16 cells (“INKmune™”) and methods of treating cancer in patients by administering INKmune™.
  • “Patents covering novel cell lines are somewhat rare in practice and form a very small number of total patents issued,” said Joshua Schoonover, Esq., in-house General Counsel for the Company.
  • INB16 is a tumor cell line which is relatively insensitive to killing by natural killer (NK) cells from healthy donors and from patients.